medicines for type 2 diabetes Flashcards

1
Q

metformin

A
  • a biguanide
  • first-line oral glucose-lowering agent for type 2
  • no weight gain (unlike insulin/sulfonylureas)
  • does not cause hypoglycaemia
  • mechanism of action uncertain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

metformin mechanism action

A
  • reduces hepatic glucose production
  • can affect multiple cellular processes like the inhibition of mitochondrial respiratory-chain complex 1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

metformin side effects

A
  • diarrhoea
  • nausea/vomiting
  • abdominal bloating/gas
  • reduced appetite
  • vitamin B12 deficiency
  • tiredness/tingling hands and feet
  • rare: lactic acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

sulfonylureas

A
  • stimulate insulin secretion from pancreatic beta cells
  • bind to ATP-gated K+ channels causing channel closure and membrane depolarisation leads to insulin secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

sulfonylureas drugs

A
  • glibenclamide
  • gliclazide
  • glipizide
  • glimepiride
  • tolbutamide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

sulfonylureas side effects

A
  • hypoglycaemia
  • weight gain (more suitable for patients who are not overweight)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

meglitinides

A
  • prandial glucose regulators
  • similar mechanism of action as sulfonylureas but rapid onset-short duration
  • taken before meals
  • repaglinide, nateglinide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

thiazolidinediones

A
  • pioglitazone
  • increase insulin sensitivity by stimulating the expression of insulin-sensitising genes
  • thiazolidinediones bind to and activate the nuclear receptor PPARy
  • side effects: water retention (oedema) and weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

GLP-1 analogues

A
  • incretin mimetics
  • release of active GLP-1 and GIP in response to an increased concentration of glucose in the digestive tract lumen
  • DPP-4 rapidly degrades incretins
  • incretin effect increased insulin release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

GLP-1 analogues medicines

A
  • exenatide (twice daily injection)
  • exenatide (once weekly injection)
  • liraglutide (once daily injection)
  • lixisenatide (once daily injection)
  • dulaglutide (once weekly injection)
  • semaglutide (once weekly injection)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DPP-4 inhibitors

A
  • gliptins
  • DPP-4 inhibitor blocks incretin degradation
  • incretins stimulate insulin secretion
  • potentiates incretin effect increases insulin release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DPP-4 medicines

A
  • sitagliptin
  • vildagliptin
  • saxagliptin
  • alogliptin
  • linagliptin
  • can all come with metformin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

alpha glucosidase inhibitor (acarbose)

A

slows down absorption of starchy foods by intestine
slow rise in blood glucose after a meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SGLT2 inhibitors

A

act by inhibiting the glucose transporter SGLT2 which functions in the kidney to mediate glucose reabsorption
examples: dapagliflozin, canagliflozin, empagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

if HbA1c rises to 48 mmol/mol

A

consider monotherapy - metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

if HbA1c rises to 58 mmol/mol

A

consider dual therapy:
- metformin + DPP-4
- metformin + pioglitazone
- metformin + sulfonylureas
- metformin + SGLT2 inhibitors

17
Q

if HbA1c rises to >58 mmol/mol

A

consider triple therapy:
- metformin + DPP-4 + sulfonylureas
- metformin + sulfonylureas - pioglitazone
- metformin + sulfonylureas + SGLT2 inhibitors
- metformin + pioglitazone + SGLT2 inhibitors

18
Q

if triple therapy fails

A

consider insulin program or-
metformin + sulfonylureas + GLP-1 mimetic

19
Q

if patient is hyperglycaemic

A

sulfonylureas + short acting insulin
- review treatment when blood glucose has been controlled

20
Q

surgery for type 2 diabetes

A

NICE recommended that all patients in UK with a BMI >35 with recent onset type 2 should be assessed for surgery